Target Price | $47.64 |
Price | $43.25 |
Potential | 10.16% |
Number of Estimates | 14 |
14 Analysts have issued a price target Exelon 2026 . The average Exelon target price is $47.64. This is 10.16% higher than the current stock price. The highest price target is $52.00 20.23% , the lowest is $39.00 9.83% . | |
A rating was issued by 19 analysts: 7 Analysts recommend Exelon to buy, 9 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Exelon stock has an average upside potential 2026 of 10.16% . Most analysts recommend the Exelon stock at Hold. |
10 Analysts have issued a sales forecast Exelon 2025 . The average Exelon sales estimate is $24.1b . This is 1.53% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $24.6b 3.70% , the lowest is $23.4b 1.18% .
This results in the following potential growth metrics:
2024 | $23.0b | 5.99% |
---|---|---|
2025 | $24.1b | 4.49% |
2026 | $24.8b | 3.05% |
2027 | $25.5b | 2.86% |
2028 | $25.8b | 1.01% |
2029 | $26.0b | 1.08% |
9 Analysts have issued an Exelon EBITDA forecast 2025. The average Exelon EBITDA estimate is $8.9b . This is 6.08% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $9.2b 10.17% , the lowest is $8.5b 2.12% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $7.9b | 5.08% |
---|---|---|
2025 | $8.9b | 12.11% |
2026 | $9.5b | 7.48% |
2027 | $10.3b | 7.93% |
2028 | $11.2b | 8.75% |
2029 | $12.0b | 7.13% |
2024 | 34.31% | 0.86% |
---|---|---|
2025 | 36.81% | 7.29% |
2026 | 38.40% | 4.32% |
2027 | 40.29% | 4.92% |
2028 | 43.37% | 7.64% |
2029 | 45.97% | 5.99% |
6 Exelon Analysts have issued a net profit forecast 2025. The average Exelon net profit estimate is $2.7b . This is 0.43% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.7b 0.90% , the lowest is $2.7b 0.22% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.5b | 5.67% |
---|---|---|
2025 | $2.7b | 10.64% |
2026 | $2.8b | 4.42% |
2027 | $3.0b | 6.05% |
2028 | $3.2b | 5.53% |
2029 | $3.3b | 5.32% |
2024 | 10.68% | 0.30% |
---|---|---|
2025 | 11.31% | 5.87% |
2026 | 11.46% | 1.33% |
2027 | 11.82% | 3.14% |
2028 | 12.35% | 4.48% |
2029 | 12.86% | 4.13% |
6 Analysts have issued a Exelon forecast for earnings per share. The average Exelon EPS is $2.70 . This is 0.00% lower than earnings per share in the financial year 2024. The highest EPS forecast is $2.71 0.37% , the lowest is $2.68 0.74% .
This results in the following potential growth metrics and future valuations:
2024 | $2.45 | 4.70% |
---|---|---|
2025 | $2.70 | 10.20% |
2026 | $2.82 | 4.44% |
2027 | $2.99 | 6.03% |
2028 | $3.15 | 5.35% |
2029 | $3.32 | 5.40% |
Current | 16.02 | 2.30% |
---|---|---|
2025 | 16.03 | 0.07% |
2026 | 15.35 | 4.24% |
2027 | 14.48 | 5.67% |
2028 | 13.72 | 5.25% |
2029 | 13.03 | 5.03% |
Based on analysts' sales estimates for 2025, the Exelon stock is valued at an EV/Sales of 3.78 and an P/S ratio of 1.81 .
This results in the following potential growth metrics and future valuations:
Current | 3.84 | 5.49% |
---|---|---|
2025 | 3.78 | 1.59% |
2026 | 3.67 | 2.96% |
2027 | 3.57 | 2.78% |
2028 | 3.53 | 1.00% |
2029 | 3.49 | 1.07% |
Current | 1.84 | 13.11% |
---|---|---|
2025 | 1.81 | 1.50% |
2026 | 1.76 | 2.96% |
2027 | 1.71 | 2.78% |
2028 | 1.69 | 1.00% |
2029 | 1.68 | 1.07% |
Analyst | Rating | Action | Date |
---|---|---|---|
UBS |
Neutral
➜
Neutral
|
Unchanged | Jun 02 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 22 2025 |
Keybanc |
Sector Weight
➜
Underweight
|
Downgrade | May 14 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 02 2025 |
Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | May 02 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | May 02 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 28 2025 |
Analyst Rating | Date |
---|---|
Unchanged
UBS:
Neutral
➜
Neutral
|
Jun 02 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
May 22 2025 |
Downgrade
Keybanc:
Sector Weight
➜
Underweight
|
May 14 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
May 02 2025 |
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
May 02 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
May 02 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Apr 28 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.